Literature DB >> 1859921

Beneficial effects of nicotine.

M E Jarvik1.   

Abstract

Nicotine in tobacco brings illness and death to millions of people. Yet nicotine in its pure form has the potential to be a valuable pharmaceutical agent. Nicotine fairly specifically binds to the cholinergic nicotinic gating site on cationic ion channels in receptors throughout the body. This action stimulates the release of a variety of neurotransmitters including especially catecholamines and serotonin. When chronically taken, nicotine may result in: (1) positive reinforcement, (2) negative reinforcement, (3) reduction of body weight, (4) enhancement of performance, and protection against; (5) Parkinson's disease (6) Tourette's disease (7) Alzheimers disease, (8) ulcerative colitis and (9) sleep apnea. The reliability of these effects varies greatly but justifies the search for more therapeutic applications for this interesting compound.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859921     DOI: 10.1111/j.1360-0443.1991.tb01810.x

Source DB:  PubMed          Journal:  Br J Addict        ISSN: 0952-0481


  20 in total

1.  Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors.

Authors:  M Zoli; M R Picciotto; R Ferrari; D Cocchi; J P Changeux
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

2.  Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model.

Authors:  Roma Kalra; Shashi P Singh; Juan C Pena-Philippides; Raymond J Langley; Seddigheh Razani-Boroujerdi; Mohan L Sopori
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

3.  (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa.

Authors:  Tanja Spoettl; Christine Paetzel; Hans Herfarth; Merouane Bencherif; Juergen Schoelmerich; Roland Greinwald; Gregory J Gatto; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2006-05-20       Impact factor: 2.571

4.  Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues.

Authors:  C A Patten; J E Martin
Journal:  Ann Behav Med       Date:  1996-09

Review 5.  Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems.

Authors:  N G Schneider; E Lunell; R E Olmstead; K O Fagerström
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 6.  Elevation of intracellular calcium levels in neurons by nicotinic acetylcholine receptors.

Authors:  M M Rathouz; S Vijayaraghavan; D K Berg
Journal:  Mol Neurobiol       Date:  1996-04       Impact factor: 5.590

7.  Nicotine effects on adults with attention-deficit/hyperactivity disorder.

Authors:  E D Levin; C K Conners; E Sparrow; S C Hinton; D Erhardt; W H Meck; J E Rose; J March
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 8.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION.

Authors:  George Bartzokis
Journal:  Adolesc Psychiatry       Date:  2005

Review 10.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.